aVaxziPen
aVaxziPen Ltd is a biotech company dedicated to transforming vaccine delivery through innovative, needle-free, solid-dose vaccine platforms. Their mission is to improve global health by providing thermostable, easy-to-administer vaccines that can reach underserved populations, reduce vaccine hesitancy, and eliminate cold chain requirements. They develop and commercialize proprietary vaccine formulations and delivery devices aimed at enhancing vaccine accessibility, safety, and cost-effectiveness.
Industries
Nr. of Employees
small (1-50)
aVaxziPen
120 A&B Olympic Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SA, United Kingdom
Patents
Products
Solid-dose vaccine microtablet
A sub-millimetre solid-dose vaccine unit produced by microtableting that dissolves after delivery and is formulated for enhanced thermostability and precise dosing.
Reusable pen applicator and disposable cartridge system
A pen-like applicator engineered to deliver solid-dose vaccine cartridges; applicator is reusable for multiple doses while cartridges are single-use and non-reusable by design.
Solid-dose vaccine microtablet
A sub-millimetre solid-dose vaccine unit produced by microtableting that dissolves after delivery and is formulated for enhanced thermostability and precise dosing.
Reusable pen applicator and disposable cartridge system
A pen-like applicator engineered to deliver solid-dose vaccine cartridges; applicator is reusable for multiple doses while cartridges are single-use and non-reusable by design.
Services
Collaborative preclinical studies to evaluate thermostability, delivery and immunogenicity of vaccine candidates formulated as solid-dose units, including stability studies at multiple temperatures and in vivo immunogenicity testing.
Production of sterile solid-dose vaccine products on isolator-based manufacturing lines and process development from laboratory to GMP scale in preparation for human clinical trials.
Design and usability testing of a reusable pen applicator and single-use cartridges to enable needle-free delivery of solid-dose vaccines with minimal training.
Collaborative preclinical studies to evaluate thermostability, delivery and immunogenicity of vaccine candidates formulated as solid-dose units, including stability studies at multiple temperatures and in vivo immunogenicity testing.
Production of sterile solid-dose vaccine products on isolator-based manufacturing lines and process development from laboratory to GMP scale in preparation for human clinical trials.
Design and usability testing of a reusable pen applicator and single-use cartridges to enable needle-free delivery of solid-dose vaccines with minimal training.
Expertise Areas
- Vaccine formulation and microtableting
- Needle-free delivery systems
- Thermostable vaccine development
- Preclinical immunogenicity and animal-model testing
Key Technologies
- Solid-dose microtableting
- Pen applicator delivery device
- Thermostable vaccine formulations
- Isolator-based sterile manufacturing
News & Updates
The Enesi management team attended the World Vaccine Congress in Barcelona, Spain, from October 10-12, 2017.
The team attended BIO-Europe in Berlin, Germany, from November 6-8, 2017.
Participation in the Jefferies Annual Healthcare Conference in London, UK, from November 15-16, 2017.
The team attended JP Morgan / Biotech Showcase in San Francisco, CA, USA, from January 8-10, 2018.
Participation in BIO-Europe Spring in Amsterdam, Netherlands, from March 12-14, 2018.
The team attended the World Vaccine Congress in Washington, DC, USA, from April 3-5, 2018.
The Enesi management team attended the World Vaccine Congress in Barcelona, Spain, from October 10-12, 2017.
The team attended BIO-Europe in Berlin, Germany, from November 6-8, 2017.
Participation in the Jefferies Annual Healthcare Conference in London, UK, from November 15-16, 2017.
The team attended JP Morgan / Biotech Showcase in San Francisco, CA, USA, from January 8-10, 2018.
Participation in BIO-Europe Spring in Amsterdam, Netherlands, from March 12-14, 2018.
The team attended the World Vaccine Congress in Washington, DC, USA, from April 3-5, 2018.